Congress Materials

Medical Information
Ireland
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

I am a healthcare professionalYes, I am a healthcare professional
SelectI am a healthcare professionalYes, I am a healthcare professional
I am a Patient/Caregiver or
Member of the General PublicNo, go back to the patient portal
SelectI am a Patient/Caregiver or
Member of the General PublicNo, go back to the patient portal

If you don't reside in Ireland, please click here

The medical information on this site is intended only for healthcare professionals in the Republic of Ireland. The products discussed herein may have different product labeling in other countries.

This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the Prescribing Information. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the Prescribing Information.
Poster
Rubin DT, Torres J, Regueiro M, Reinisch W, Prideaux L, Kotze PG, Tan FH, Gardiner S, Mundayat R, Cadatal MJ, Ng SC February 19, 2022 ECCO 2022 Ulcerative Colitis

Association between smoking status and the efficacy and safety of tofacitinib in patients with Ulcerative Colitis: Data from the tofacitinib clinical programme

View Presentation
Poster
Rubin DT, Vavricka SR, Armuzzi A, Dubinsky MC, Sharara AI, Modesto I, Fellmann M, Liguori G, Lawendy N, Cadatal MJ, Lichtenstein GR February 19, 2022 ECCO 2022 Ulcerative Colitis

Efficacy and safety of tofacitinib in Ulcerative Colitis patients with extraintestinal manifestations in OCTAVE Open

View Presentation
Oral Presentation
Hassan-Zahraee M, Ye Z, Xi L, Banerjee A, He W, Dushin E, Lee J, Altintas E, Romatowski J, Leszczyszyn J, Danese S, Sandborn WJ, Banfield C, Gale JD, Peeva E, Vincent M, Hyde C, Longman R, Hung KE February 19, 2022 ECCO 2022 Ulcerative Colitis

Integrated tissue transcriptomic and serum proteomic interrogation reveals biomarkers for endoscopic improvement and histologic remission after JAK3/TEC inhibition with ritlecitinib (PF-06651600) in ulcerative colitis (UC) (phase 2 Vibrato study)

View Presentation
Poster
Allegretti JR, Gecse KB, Chiorean MV, Argollo M, Guo X, Lawendy N, Su C, Mundayat R, Paulissen J, Salese L, Irving PM February 19, 2022 ECCO 2022 Ulcerative Colitis

Rectal bleeding and stool frequency improvement with tofacitinib dose escalation to 10 mg BID in patients with Ulcerative Colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: Results from OCTAVE Open

View Presentation
Poster
Allegretti JR, Gecse KB, Chiorean MV, Argollo M, Guo X, Lawendy N, Su C, Mundayat R, Paulissen J, Salese L, Irving PM February 19, 2022 ECCO 2022 Ulcerative Colitis

Rectal bleeding and stool frequency improvement with tofacitinib retreatment in patients with Ulcerative Colitis after treatment interruption: Results from OCTAVE Open

View Presentation
Poster
Biedermann L, Dubinsky MC, Vermeire S, Fellmann M, Gardiner S, Hur P, Mundayat R, Panés J, Rubin DT February 19, 2022 ECCO 2022 Ulcerative Colitis

Sustained improvement in health-related quality of life outcomes in patients with Ulcerative Colitis with long-term tofacitinib treatment in the open-label extension study, OCTAVE Open

View Presentation
Oral Presentation
Sandborn WJ, D'Haens GR, Sands BE, Panaccione R, Ng SC, Lawendy N, Kulisek N, Guo X, Mundayat R, Su C, Panés J February 19, 2022 ECCO 2022 Ulcerative Colitis

Tofacitinib for the treatment of ulcerative colitis: an integrated summary of safety data from the global OCTAVE and RIVETING clinical trials

View Presentation